TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01097616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant High Dose (HD)
Description: Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants \<65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant Low Dose (LD)
Description: Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants \<65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Matching placebos to suvorexant 40 mg and 20 mg for participants \<65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
Study: NCT00915811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30mg/m2 intravenously daily on days -9 to -5 inclusive of stem cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulphan
Description: Busulphan 0.8mg/kg intravenously 6 hourly on days -4 and -3 of stem cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme
Description: Thymoglobuline will be given intravenously over a minimum of 6 hours for the first two doses and 4 hours for the subsequent doses. Acute side effects of ATG appear to be reduced if a very low dose is given for the first injection. Thymoglobuline 0.5mg/kg iv on day -4, 1.5mg/kg/day on day -3; and 2mg/kg/day iv on day -2 to -1 inclusive.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haematopoietic stem cell infusion
Description: The source of stem cells will be PBSC wherever possible. Patients whose donors decline or are unable to donate PBSC will be transplanted with marrow cells.
Study: NCT02952547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of DWC20155 and DWC20156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of DWC20155 and DWC20156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1366 Tab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1366 Tab.
Study: NCT04170075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: Undergo WBV
Study: NCT02572687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study: NCT04164212

Intervention type: DRUG
Group type: OTHER
Intervention: Flumist Quadrivalent Nasal Product
Description: FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
Study: NCT03396393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin tablet
Description: DHA tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet
Study: NCT02365857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine & Bupivacaine.
Description: Intrathecal injection of Dexmedetomidine \& Bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine & Bupivacaine.
Description: Intrathecal injection of Dexmedetomidine \& Bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine & Bupivacaine.
Description: Intrathecal injection of Dexmedetomidine \& Bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Only.
Description: Intrathecal injection of Bupivacaine only.
Study: NCT00674167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Three cycles of chemotherapy will be administered before surgery with docetaxel at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
Study: NCT03021525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized Goal Directed Therapy
Description: The trial intervention period will commence from the induction of anesthesia until 8 hours after surgery, or until discharging from the postoperative intensive or intermediate care unit. All patients in the intervention group receive basic vital sign monitoring. For inotropic support dobutamine, and as vasopressor norepinephrine are drugs of choice. Hemodynamic management is performed according to standard treatment until an arterial line is placed. The signal of the arterial line is then processed either by calibrated or non-calibrated pulse contour analysis for pulse pressure variation (PPV) and cardiac index (CI) measurement. Fluid challenge will be performed by infusion of 500 ml in \<15 minute. Choice of fluid in case of indicated fluid loading is determined on basis of the recent guideline for intravasal volume therapy. Patients receive fluids and vasoactive agents following a protocol of individualized parameters regularly achieved by extended hemodynamic monitoring.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Patients in the control group will be treated according to established basic treatment goals (heart rate \<100 bpm, mean arterial pressure \>65 mmHg, SpO2\>94%, and core temperature \>36° C). Basic anesthesiological monitoring by five-lead-electrocardiogram, pulse oximetry, non-invasive blood pressure monitoring and capnography is performed in every patient of the control group. Placement of an arterial and central venous line, as well as fluid and catecholamines administration, are at the discretion of the treating clinician.
Study: NCT02572687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Administered IV
Study: NCT00674167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
Study: NCT01003587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: District health information package
Description: The intervention package consists of:~* A report on disease burden, disease control priorities and health system performance in India~* Condensed fact sheet based on the report~* District health report cards (DRCs) comparing performance on key health indicators with other districts, information on causes of death in each district, and actionable messages to reduce deaths in the district~* Customized speech for district level officials detailing key actions to reduce deaths~* Reminder materials including poster version of the DRCs and video on key points and actionable messages
Study: NCT01342640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Recommended starting dose 1.2 micrograms/kg subcutaneously every 4 weeks (depending on patient's weight). Dose adjustment may be required in the event of inadequate or excessive treatment response.
Study: NCT00866294

Intervention type: DRUG
Group type: OTHER
Intervention: paroxetine IR 10mg tablet
Description: 1 or 2 tablets once a day

Intervention type: DRUG
Group type: OTHER
Intervention: paroxetine IR 20mg tablet
Description: 1 tablet once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matched placebo to paroxetine IR 10mg or 20mg
Description: 1 or 2 tablets once a day
Study: NCT04046094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Ascorbic Acid Intravenous
Study: NCT00674167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycle.
Study: NCT04542538

Intervention type: OTHER
Intervention: No intervention, observational study

Intervention type: OTHER
Intervention: No intervention, observational study

Intervention type: OTHER
Intervention: No intervention, observational study
Study: NCT03031795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study: NCT00866294

Intervention type: DRUG
Group type: OTHER
Intervention: matched placebo to paroxetine IR 10mg or 20mg
Description: 1 or 2 tablets once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo to paroxetine IR 10mg or 20mg
Description: 1 or 2 tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine CR 12.5mg tablet
Description: 1 or 2 tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine CR 25mg tablet
Description: 1 or 2 tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matched placebo to paroxetine CR 12.5mg or 25mg
Description: 1 or 2 tablets once a day

Intervention type: DRUG
Group type: OTHER
Intervention: matched placebo to paroxetine CR 12.5mg or 25mg
Description: 1 or 2 tablets once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo to paroxetine CR 12.5mg or 25mg
Description: 1 or 2 tablets once a day
Study: NCT02935881

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radio Frequency Ablation (RFA) (Stretta Procedure)
Description: Radio Frequency Ablation (RFA) for the treatment of refractory gastroesophageal reflux disease.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Stretta device will be used but Radio Frequency Ablation (RFA) will not be generated.
Study: NCT00970203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: androgen ablation (AA)
Description: Lupron 22.5 mg or Zoladex 10.8 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: androgen ablation (AA)
Description: Lupron 22.5 mg or Zoladex 10.8 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC1 vaccine
Description: 3-5 x 10e6 cells total

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC1 vaccine
Description: 3-5 x 10e6 cells total
Study: NCT01686984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altered breath
Study: NCT01790061

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardized FMT
Description: Fecal microbiota transplantation by gastroscopy administration of fresh or frozen bacteria from healthy donor to the mid-gut or whole colon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional treatments
Description: Medications
Study: NCT00564629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen plus oral placebo
Description: Single dose of 1 gm IV acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral acetaminophen plus IV placebo
Description: Single dose of 1 g PO APAP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reference standard endotoxin (RSE)
Description: To subjects in both study arms: Administration of a 1 ng/kg body weight test dose of RSE to induce fever and test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference standard endotoxin (RSE)
Description: To subjects in both study arms: Administration of a 1 ng/kg body weight test dose of RSE to induce fever and test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
Study: NCT01347567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventions with heart failure medications
Description: Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Interventions with heart failure medications
Description: Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interventions with heart failure medications
Description: Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
Study: NCT02243124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cenersen
Description: cenersen is a phosphorothioate antisense oligonucleotide that down-regulates the production of both wild-type and mutant p53, and has a RNase H-dependent mechanism of action

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cenersen
Description: cenersen is a phosphorothioate antisense oligonucleotide that down-regulates the production of both wild-type and mutant p53, and has a RNase H-dependent mechanism of action

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cenersen
Description: cenersen is a phosphorothioate antisense oligonucleotide that down-regulates the production of both wild-type and mutant p53, and has a RNase H-dependent mechanism of action

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Optionally, Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Optionally, Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Optionally, Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
Study: NCT03311178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
Study: NCT02696512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypharmacy using FDA-approved products
Description: Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12, Methylfolate, Rasagiline, Amantadine, Naltrexone and Levodopa/carbidopa.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Median Nerve Stimulation (MNS)
Description: 40 cycle/second (gamma range) asymmetric, 2 ms wavebands with 300 µs bursts at 20 milliamps bilaterally (randomized left arm and right arm sequencing algorithm) applied 20 seconds on and 40 seconds off for 8 hours per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutraceutical Supplementation
Description: Battery of nutraceuticals provided through a 12-week schedule including: Acidophilus, Alpha-Lipoic Acid, Acetyl L-Carnitine,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care treatment
Study: NCT01373177

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bayley Scales of Infant Development-II
Description: Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-II was published in 1993. BSID-II provides normative data from two scales - Mental Development Index (MDI), and Psychomotor Development Index (PDI).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bayley Scales of Infant Development-II
Description: Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-II was published in 1993. BSID-II provides normative data from two scales - Mental Development Index (MDI), and Psychomotor Development Index (PDI).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bayley Scales of Infant Development-III
Description: Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-III was released in 2006. BSID-III provides normative data from five scales - Cognitive, Language, Motor, Social-Emotional, and Adaptive.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bayley Scales of Infant Development-III
Description: Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-III was released in 2006. BSID-III provides normative data from five scales - Cognitive, Language, Motor, Social-Emotional, and Adaptive.
Study: NCT03488810

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Dose escalated Intensity-Modulated Radiation therapy (IMRT) with conventional fractionation, hypofractionation and prostate brachytherapy are allowed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Dose escalated Intensity-Modulated Radiation therapy (IMRT) with conventional fractionation, hypofractionation and prostate brachytherapy are allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240 mg PO daily, started the same day as the first LHRHa injection, for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luteinising Hormone Releasing Hormone analog agonist (LHRHa)
Description: 2 injections of a three-monthly LHRH agonist depot

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinising Hormone Releasing Hormone analog agonist (LHRHa)
Description: 2 injections of a three-monthly LHRH agonist depot

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-steroidal anti-androgen
Description: Non-steroidal anti-androgen (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection
Study: NCT04247932

Intervention type: BEHAVIORAL
Intervention: Active labor market intervention
Description: Behavior change intervention

Intervention type: BEHAVIORAL
Intervention: Active labor market intervention
Description: Behavior change intervention
Study: NCT03246269

Intervention type: DIAGNOSTIC_TEST
Intervention: MoCA
Study: NCT01453192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Introduction of Raltegravir 2 days after renal transplantation within an antiretroviral regimen without ritonavir boosted antiprotease
Study: NCT04281927

Intervention type: DEVICE
Intervention: Monitoring with wearable (the tested device) and Holter ECG (eMotion Faros 90)
Description: Participants will use the wearable (the tested device) to record at least 2 minutes of photoplethysmography and 6-lead ECG. In addition, each subject will be monitored with synchronous ECG Holter monitoring (with eMotion Faros 90).

Intervention type: DEVICE
Intervention: Monitoring with wearable (the tested device) and Holter ECG (eMotion Faros 90)
Description: Participants will use the wearable (the tested device) to record at least 2 minutes of photoplethysmography and 6-lead ECG. In addition, each subject will be monitored with synchronous ECG Holter monitoring (with eMotion Faros 90).
Study: NCT01759134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post discharge formula
Description: Babies will be given either materna sensitive or similac neosure
Study: NCT04534465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (MiraLAX, BAY81-8430)
Description: Oral solution, 17g polyethylene glycol, one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (MiraLAX, BAY81-8430)
Description: Oral solution, 17g polyethylene glycol, one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (MiraLAX, BAY81-8430)
Description: Oral solution, 17g polyethylene glycol, one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (MiraLAX, BAY81-8430)
Description: Oral solution, 17g polyethylene glycol, one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (MiraLAX, BAY81-8430)
Description: Oral solution, 17g polyethylene glycol, one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Oral, 2g, 4g, 6g, 8g and 10g mannitol, one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Oral, 2g, 4g, 6g, 8g and 10g mannitol, one time
Study: NCT04281927

Intervention type: DEVICE
Intervention: Monitoring with wearable (the tested device) and Holter ECG (eMotion Faros 90)
Description: Participants will use the wearable (the tested device) to record at least 2 minutes of photoplethysmography and 6-lead ECG. In addition, each subject will be monitored with synchronous ECG Holter monitoring (with eMotion Faros 90).